Skip to main content
Marcel Nijland
dr.

I work as a hematologist and my main focus is on patients with aggressive B-cell lymphomas and CNS lymphomas. My research is centered on the application of novel diagnostic and therapeutic strategies into clinical trials. These include imaging-studies like 18F-FDG-PET, Zr-Brentuximab-PET and Zr-atezolizumab-PET. In addition, I aim to implement novel strategies to measure minimal residual disease, and prognostic gene expression profiles in DLBCL. Linked to this I also focus on mutational analysis to study clonal evolution and prognostic / predictive values of mutations. These studies are carried out in a close collaboration with HOVON and other departments in the UMCG.

Prognostic Model to Predict Post-Autologous Stem-Cell Transplantation Outcomes in Classical Hodgkin Lymphoma
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Purpose: Our aim was to capture the biology of classical Hodgkin lymphoma (cHL) at the time of relapse and discover novel and robust biomarkers that predict outcomes after autologous stem-cell transplantation (ASCT). Materials and Methods: We performed digital gene expression profiling on a cohort of 245 formalin-fixed, paraffin-embedded tumor specimens from 174 patients with cHL, including 71 with biopsies taken at both primary diagnosis and relapse, to investigate temporal gene expression differences and associations with post-ASCT outcomes. Relapse biopsies from a training cohort of 65 patients were used...
Fong Chun Chan, Anja Mottok, Alina S. Gerrie, Maryse Power, Marcel Nijland, Arjan Diepstra, Anke van den Berg, Peter Kamper, Francesco d'Amore, Alexander Lindholm d'Amore, Stephen Hamilton-Dutoit, Kerry J. Savage, Sohrab P. Shah, Joseph M. Connors, Randy D. Gascoyne, David W. Scott, Christian Steidl
Primary Polyomavirus Infection, Not Reactivation, as the Cause of Trichodysplasia Spinulosa in Immunocompromised Patients
Published in: The Journal of Infectious Diseases
Classic human polyomaviruses (JC and BK viruses) become pathogenic when reactivating from latency. For the rare skin disease trichodysplasia spinulosa, we show that manifestations of the causative polyomavirus (TSPyV) occur during primary infection of the immunosuppressed host. High TSPyV loads in blood and cerebrospinal fluid, sometimes coinciding with cerebral lesions and neuroendocrine symptoms, marked the acute phase of trichodysplasia spinulosa, whereas initiation and maturation of TSPyV seroresponses occurred in the convalescent phase. TSPyV genomes lacked the rearrangements typical for reactivating polyomaviruses. These findings demonstrate the clinical importance of...
Els van der Meijden, Barbara Horváth, Marcel Nijland, Karin de Vries, Emöke Rácz, Gilles F Diercks, Annelies E de Weerd, Marian C Clahsen-van Groningen, Caroline S van der Blij-Brouwer, Arnulfo J van der Zon, Aloys C M Kroes, Klaus Hedman, Jeroen J A van Kampen, Annelies Riezebos-Brilman, Mariet C W Feltkamp
A patient with a large renal tumor: not always for the urologist
Published in: Tijdschrift voor Urologie
A 68-year old patient presented with flank pain caused by a large renal mass. A nephrectomy was performed because renal cell carcinoma was suspected. Pathological examination showed a diffuse large B‑cell lymphoma. Primary renal manifestation of a lymphoma is rare. The diagnosis is often missed or only recognized after a nephrectomy is performed. A primary renal lymphoma must be considered when radiologically a hypovascular, diffuse growing process is seen, without the characteristic signs of renal cell carcinoma, like calcifications and vascular invasion. Diagnosis can be confirmed by biopsies and, once histologically proven, curative treatment with chemo-immunotherapy...
Locally advanced basal cell carcinoma of the face with surprising response to R-CHOP
Treatment of choice for high risk basal cell carcinoma (BCC) of the face is Mohs micrographic surgery. Radiotherapy can be applied when surgery will result in cosmetic and/or functional morbidity. Patients with locally advanced or metastatic BCC can be treated with vismodegib or sonidegib. R-CHOP is used frequently in the treatment of several B-cell non-Hodgkin lymphomas, but effectiveness in the treatment of BCC is unknown. Here we present an impressive clinical and histological response of a locally advanced BCC of the face after treatment with R-CHOP for diffuse...
M. C. Urgert, M. Nijland, H. C. De Vijlder, G. F.H. Diercks, A. K.L. Reyners, J. B. Terra
Treatment of initial parenchymal central nervous system involvement in systemic aggressive B-cell lymphoma
Published in: Leukemia and Lymphoma
Central nervous system (CNS) involvement in systemic B-cell non-Hodgkin lymphoma (B-NHL) at diagnosis (sysCNS) is rare. We investigated the outcome of 21 patients with sysCNS, most commonly diffuse large B-cell lymphoma, treated with high dose methotrexate (HD-MTX) and R-CHOP. The median number of cycles of HD-MTX and R-CHOP was 4 (range 1-8) and 6 (range 0-8), respectively. Consolidative whole brain radiotherapy (WBRT) was given to 33% (7/21) patients. With a median follow-up of 44 months the 3-year progression free survival (PFS) and overall survival (OS) were 45% (95%CI...
Marcel Nijland, Anne Jansen, Jeanette K. Doorduijn, Roelien H. Enting, Jacoline E. C. Bromberg, Hanneke C. Kluin-Nelemans